Integrative genomic and transcriptomic profiling identifies HSPA5 as a central player in hepatocellular carcinoma pathogenesis Taimoor Riaz, Sumbal Rasheed, Muhammad Zubair Computational Biology and Chemistry.2026; 120: 108722. CrossRef
Diagnostic Test Accuracy of Contrast‐Enhanced Ultrasound With Sonazoid for Assessment of Focal Liver Lesions: A Systematic Review and Meta‐Analysis Yongqing Tang, Shun‐ichi Sasaki, Joshua Hawley, Aurélie Peillon, Anders Sjöström, Adolfo Fuentes‐Alburo, Francois Tranquart Journal of Clinical Ultrasound.2025; 53(3): 510. CrossRef
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults Donghee Kim, Won Kim, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(1): e5. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
Dual-Functional Micelles for Codelivery of Sorafenib and Dehydrodiisoeugenol in Treatment of Hepatocellular Carcinoma Su-Yu Yang, Shu-Tong Li, Tian-Hua Li, De-Jin Ma, Jun-Jie Yu, Yang Liu, Yang Yu, Xue-Tao Li, Juan Zang, Zi-Min Yuan, Liang Kong ACS Applied Nano Materials.2025; 8(11): 5355. CrossRef
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021 Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal, Hepatology.2025; 82(5): 1274. CrossRef
A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition Chencheng Li, Xiu Hong, Sarra Setrerrahmane, Xiaoyi Sun, Xue Zhang, Hanmei Xu Cancers.2025; 17(17): 2932. CrossRef
MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting CPT1A and ACSL4 Chinnatam Phetkong, Thammachanok Boonto, Pannathon Thamjamrassri, Chaiyaboot Ariyachet, Pisit Tangkijvanich BioImpacts.2025; 15: 31075. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Validation of prognostic models for predicting postsurgical outcomes in intrahepatic cholangiocarcinoma patients using a multicenter cohort Dong Hwan Kim, Sang Hyun Choi, Sehee Kim, Woohyung Lee, Hyung-Don Kim, Hyungjin Rhee, Eun-Suk Cho, Suk-Keu Yeom, Sumi Park, Seung Soo Lee, Mi-Suk Park International Journal of Surgery.2025; 111(10): 7032. CrossRef
Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature Xian-Shuai Kou, Fan-Fan Li, Yun Meng, Jian-Ming Zhao, Sheng-Fen Liu, Lan Zhang World Journal of Gastrointestinal Oncology.2024; 16(5): 2225. CrossRef
Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma Omkolsoum Alhaddad, Asmaa Gomaa, Merhan El Shamandy, Mohamed Kohla, Ahmed Edrees, Reham Ashour Romanian Journal of Internal Medicine.2024; 62(4): 430. CrossRef
Phytochemicals and Their Nanoformulations for Targeting Hepatocellular Carcinoma: Exploring Potential and Targeting Strategies Safia Obaidur Rab, R. Roopashree, Farag M. A. Altalbawy, M. Ravi Kumar, Mamata Chahar, Manmeet Singh, Aziz Kubaev, Hassan Thoulfikar A. Alamir, Faraj Mohammed, Abed J. Kadhim, Merwa Alhadrawi Cell Biochemistry and Function.2024;[Epub] CrossRef
Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma Ping Chen, Chengchen Yang, Ke Ren, Mingzhi Xu, Chenwei Pan, Xuewei Ye, Lanjuan Li Frontiers in Immunology.2024;[Epub] CrossRef
Current epidemiology of chronic liver disease Richie Manikat, Aijaz Ahmed, Donghee Kim Gastroenterology Report.2023;[Epub] CrossRef
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extra-hepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more long-term mortality data may demonstrate an independent association between NAFLD and mortality.
Citations
Citations to this article as recorded by
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Rohit Loomba, Mark Thursz, Mark Woodward Liver International.2026;[Epub] CrossRef
Secondary Growth Hormone Deficiency That Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, Chisa Yamamoto, Kohei Ohta, Yuya Matsuo, Yuya Nishio, Yusuke Komeda, Shoma Kikukawa, Kyohei Matsuura, Hideki Matsuo, Masakazu Uejima, Kei Moriya Internal Medicine.2025; 64(3): 387. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
The Fibrosis-4 index predicts all-cause mortality in a cohort of patients at high cardiovascular risk partly through glomerular filtration rate reduction Antonio Mirijello, Gabriella Pacilli, Antonio Siena, Antonio Mangiacotti, Maria Maddalena D'Errico, Daria Dilalla, Olga Lamacchia, Andrea Fontana, Massimiliano Copetti, Pamela Piscitelli, Giovanni Targher, Salvatore A. De Cosmo Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103768. CrossRef
Secondhand Smoke Exposure and Metabolic Dysfunction-associated Steatotic Liver Disease in US Adolescents Donghee Kim, Brandon J. Perumpail, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical Gastroenterology and Hepatology.2025; 23(4): 665. CrossRef
Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply Yewan Park, Jooyi Jung, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2025; 61(2): 400. CrossRef
Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease Ming-Hua Zheng, Amedeo Lonardo World Journal of Gastroenterology.2025;[Epub] CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Baokai Sun, Likun Zhuang Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen J. Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari, Mattias Ekstedt, Terry Cheuk-Fung Yip, Grace European Journal of Gastroenterology & Hepatology.2025; 37(3): 358. CrossRef
Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease Yu-Ming Cheng, Shao-Wen Wang, Ching Wang, Chia-Chi Wang Tzu Chi Medical Journal.2025; 37(2): 152. CrossRef
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study Qian He, Xinyue Liu, Guoyong Ding, Yiying Wang, Xiaoting Luo, Wenyuan Cao, Weijia Xing BMC Public Health.2025;[Epub] CrossRef
Novel pyranopyridine derivatives and their radiolabeled nanoconjugates: An augmented approach for targeted cancer theranostics Hesham A. Shamsel-Din, Mohamed M. Swidan, Ahmed B. Ibrahim, Mohamed A. Motaleb, Tamer M. Sakr Journal of Drug Delivery Science and Technology.2025; 107: 106802. CrossRef
Metabolic dysfunction-associated steatotic liver disease in adults Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba Nature Reviews Disease Primers.2025;[Epub] CrossRef
Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020 Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu Frontiers in Physiology.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e183. CrossRef
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): 382. CrossRef
Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek BMC Gastroenterology.2025;[Epub] CrossRef
Response to the Letter to the Editor: What Is the Optimal Anti‐Diabetic Regimen Among CHB and T2DM Patients? Beom Kyung Kim Liver International.2025;[Epub] CrossRef
The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai Ultrasonography.2025; 44(3): 189. CrossRef
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2025;[Epub] CrossRef
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease in Children with Down Syndrome at a Tertiary Care Center Maria D. Karaceper, Maria-Jose Villegas, Sanathan Sadh, Sierra Kawesa, Jamie Strain, Asha Nair, Alissa Dupuis, Mary Pothos, Ming-Hua Zheng, Mohit Kehar Journal of Clinical Medicine.2025; 14(9): 3239. CrossRef
The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco Journal of Clinical Medicine.2025; 14(11): 3821. CrossRef
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade Hideyuki Tamai, Jumpei Okamura Hepatology Research.2025; 55(9): 1274. CrossRef
Association between impaired sensitivity to thyroid hormones and sedentary behavior: a cross-sectional study Hangzhou Yang, Jie Kang, Lingkang Dong, Zihan Lin, Qixian Lin, Bo Wu Frontiers in Medicine.2025;[Epub] CrossRef
ECM formation and degradation during fibrosis, repair, and regeneration Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan npj Metabolic Health and Disease.2025;[Epub] CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
The Burden of Nonmalignant Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021 Qichao Ge, Yuan Lin, Mingwang Wang, Jianwei Zhu, Qingqing Zhang, Junjun Wang, Yufei Yang, Hanjing Zhangdi, Yuecheng Guo, Shanjuan Wang, Lungen Lu Food Science & Nutrition.2025;[Epub] CrossRef
The association between serum pinenes and non-alcoholic fatty liver disease based on the NHANES 2013–2014 Tuo Xiao, Xue Xing, Lulu Sun, Jin Shang Ecotoxicology and Environmental Safety.2025; 302: 118712. CrossRef
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson JMIR Cardio.2025; 9: e72074. CrossRef
Reliability of Ultrasonic Hepatorenal Indices in Assessing Hepatic Steatosis: A Systematic Review and Meta‐Analysis Jin‐Li Wang, Jian Dong, Si‐Rui Wang, Chun‐Li Cao, Jin Tong, WenXiao Li, Ting‐Ting Du, Ting‐Ting He, Xiao‐Wu Yuan, Jun Li, Hong Zhai Journal of Clinical Ultrasound.2025;[Epub] CrossRef
The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari Inflammopharmacology.2025; 33(9): 5583. CrossRef
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(5): 758. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis Francisco Idalsoaga, Luis Antonio Díaz, Saleh Alghsoon, Bishoy Lawendy, Neha Sharma, Hailemichael Desalegn, Yuhong Yuan, My Ha, Jessica Le, John K. MacDonald, Marco Arrese, Rohit Loomba, Vipul Jairath, Mohammad Qasim Khan, Juan Pablo Arab Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel World Journal of Gastrointestinal Pharmacology and Therapeutics.2025;[Epub] CrossRef
Sex-specific differences in the prognostic value of METS-IR for long-term outcomes in patients with MASLD and advanced liver fibrosis: a nationwide study Binbin Song, Yuan Zhou, Rui Su, Yan Wang, Song Chen, Wenjin Chen European Journal of Medical Research.2025;[Epub] CrossRef
Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun Liver International.2024; 44(4): 944. CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo Gut and Liver.2024; 18(2): 283. CrossRef
Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease Richie Manikat, Aijaz Ahmed, Donghee Kim Alimentary Pharmacology & Therapeutics.2024; 59(7): 893. CrossRef
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2024; 60(1): 33. CrossRef
Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Journal of Gastroenterology and Hepatology.2024; 39(9): 1950. CrossRef
Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge Mohamad Jamalinia, Amedeo Lonardo Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield Annals of Hepatology.2024; 29(5): 101528. CrossRef
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes David R. Riley, Theresa Hydes, Gema Hernadez, Sizheng S. Zhao, Uazman Alam, Daniel J. Cuthbertson Liver International.2024; 44(10): 2538. CrossRef
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease Do Seon Song Gut and Liver.2024; 18(4): 562. CrossRef
Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu Cardiovascular Diabetology.2024;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura Medicina.2024; 60(8): 1330. CrossRef
Contemporary awareness of nonalcoholic fatty liver disease and viral hepatitis based on the stage Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed The American Journal of the Medical Sciences.2024; 368(6): 685. CrossRef
High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang Scientific Reports.2024;[Epub] CrossRef
Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu Gut and Liver.2024; 18(5): 888. CrossRef
Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research Ewelina Książek, Zuzanna Goluch, Marta Bochniak Nutrients.2024; 16(17): 2940. CrossRef
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Clinical and Molecular Hepatology.2024; 30(4): 982. CrossRef
Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada, Jose M. Arbones-Mainar Metabolites.2024; 14(11): 618. CrossRef
Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity Donghee Kim, George Cholankeril, Aijaz Ahmed Journal of Obesity & Metabolic Syndrome.2024; 33(4): 326. CrossRef
Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination Yuanchen Zhou, Shaojie Duan, Rongrui Wang, Jialiang Chen, Shukun Yao Frontiers in Endocrinology.2023;[Epub] CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays Menna M. Abdelshaheed, Hussein I. El Subbagh, Mohamed A. Tantawy, Reem T. Attia, Khairia M. Youssef, Iten M. Fawzy RSC Advances.2023; 13(23): 15689. CrossRef
Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease Ju-Yeon Cho, Won Sohn Gut and Liver.2023; 17(4): 487. CrossRef
Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687 Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic Nutrients.2023; 15(13): 2907. CrossRef
Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD Nuria Perez-Diaz-del-Campo, Gabriele Castelnuovo, Chiara Rosso, Aurora Nicolosi, Marta Guariglia, Eleonora Dileo, Angelo Armandi, Gian Paolo Caviglia, Elisabetta Bugianesi Nutrients.2023; 15(13): 3018. CrossRef
Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease Ho Soo Chun Gut and Liver.2023; 17(4): 485. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe Clinical and Molecular Hepatology.2023; 29(4): 987. CrossRef
Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity T.S. Krolevets, M.I. Syrovenko, M.A. Livzan Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43. CrossRef
Current epidemiology of chronic liver disease Richie Manikat, Aijaz Ahmed, Donghee Kim Gastroenterology Report.2023;[Epub] CrossRef
First
Prev
